Alkem Laboratories Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 5/6
Alkem Laboratories verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 6.7%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 17%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 11.1%. Die Eigenkapitalrendite von Alkem Laboratories beträgt 16.9% und die Nettomargen betragen 14.2%.
Wichtige Informationen
6.8%
Wachstumsrate der Gewinne
6.8%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 17.5% |
| Wachstumsrate der Einnahmen | 10.9% |
| Eigenkapitalrendite | 19.4% |
| Netto-Marge | 16.1% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You
Sep 24
Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 03Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 27Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00
Jul 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 27Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00
Jun 13Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 01Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)
May 22Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease
Dec 27Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 14Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Aug 02Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Jul 07Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
May 22We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt
Mar 27Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Dec 26These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well
Sep 20Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00
Jul 27Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 13Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jun 11Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
May 23Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Mar 06Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Feb 21Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Feb 08Should You Be Adding Alkem Laboratories (NSE:ALKEM) To Your Watchlist Today?
Jan 09Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Nov 30Here's Why Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt Responsibly
Nov 17Aufschlüsselung der Einnahmen und Ausgaben
Wie Alkem Laboratories Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 127,317 | 20,542 | 30,675 | 0 |
| 31 Mar 24 | 126,676 | 17,958 | 30,329 | 0 |
| 31 Dec 23 | 126,344 | 15,732 | 30,394 | 0 |
| 30 Sep 23 | 123,514 | 14,329 | 29,926 | 0 |
| 30 Jun 23 | 119,906 | 11,433 | 30,081 | 0 |
| 31 Mar 23 | 115,993 | 9,842 | 29,726 | 0 |
| 31 Dec 22 | 111,805 | 10,208 | 27,081 | 0 |
| 30 Sep 22 | 107,586 | 10,917 | 26,536 | 0 |
| 30 Jun 22 | 104,792 | 13,051 | 25,772 | 0 |
| 31 Mar 22 | 106,342 | 16,456 | 25,769 | 0 |
| 31 Dec 21 | 103,425 | 17,780 | 22,660 | 0 |
| 30 Sep 21 | 100,416 | 17,033 | 22,048 | 0 |
| 30 Jun 21 | 96,044 | 16,311 | 21,183 | 0 |
| 31 Mar 21 | 88,650 | 15,850 | 19,807 | 0 |
| 31 Dec 20 | 87,218 | 15,338 | 21,217 | 0 |
| 30 Sep 20 | 85,971 | 14,648 | 21,076 | 0 |
| 30 Jun 20 | 84,984 | 13,636 | 20,892 | 0 |
| 31 Mar 20 | 83,444 | 11,271 | 20,853 | 0 |
| 31 Dec 19 | 81,484 | 11,057 | 20,347 | 0 |
| 30 Sep 19 | 78,929 | 9,262 | 19,855 | 0 |
| 30 Jun 19 | 75,478 | 8,098 | 19,237 | 0 |
| 31 Mar 19 | 73,572 | 7,605 | 18,728 | 0 |
| 31 Dec 18 | 70,157 | 6,602 | 17,762 | 0 |
| 30 Sep 18 | 68,318 | 6,293 | 17,412 | 0 |
| 30 Jun 18 | 67,788 | 6,955 | 17,212 | 0 |
| 31 Mar 18 | 63,918 | 6,309 | 16,555 | 0 |
| 31 Dec 17 | 60,044 | 7,009 | 15,102 | 0 |
| 30 Sep 17 | 57,285 | 7,626 | 14,699 | 0 |
| 30 Jun 17 | 55,019 | 7,248 | 14,245 | 0 |
| 31 Mar 17 | 56,875 | 8,920 | 13,910 | 0 |
| 31 Dec 16 | 56,933 | 7,732 | 13,497 | 0 |
| 30 Sep 16 | 54,992 | 7,267 | 12,977 | 0 |
| 30 Jun 16 | 52,419 | 7,108 | 9,430 | 0 |
| 31 Mar 16 | 49,248 | 7,416 | 11,699 | 0 |
| 31 Dec 15 | 47,975 | 8,189 | 15,267 | 220 |
| 30 Sep 15 | 44,556 | 7,227 | 15,252 | 291 |
| 30 Jun 15 | 40,459 | 5,781 | 11,940 | 150 |
| 31 Mar 15 | 37,434 | 3,916 | 9,032 | 0 |
| 31 Mar 14 | 31,191 | 4,353 | 10,466 | 210 |
Qualität der Erträge: ALKEM hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: ALKEMDie aktuellen Gewinnspannen (14.2%) sind höher als im letzten Jahr (8.5%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: ALKEMIn den letzten 5 Jahren sind die Gewinne von 6.7% jährlich gestiegen.
Beschleunigtes Wachstum: ALKEMDas Gewinnwachstum des Unternehmens im letzten Jahr (82.5%) übertrifft seinen 5-Jahres-Durchschnitt (6.7% pro Jahr).
Erträge im Vergleich zur Industrie: ALKEM Das Gewinnwachstum im vergangenen Jahr (82.5%) übertraf das der Branche Pharmaceuticals 18.4% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: ALKEMDie Eigenkapitalrendite des Unternehmens (16.9%) wird als niedrig angesehen.